NCT07000162 (LART) is a Phase 2 clinical trial of Lattice radiation therapy in Cancer, sponsored by Azienda USL Reggio Emilia - IRCCS.

Who is sponsoring NCT07000162?

NCT07000162 is sponsored by Azienda USL Reggio Emilia - IRCCS.

What drugs are being tested in NCT07000162?

Interventions in NCT07000162: Lattice radiation therapy.

What condition does NCT07000162 study?

NCT07000162 studies Cancer, Palliative Radiotherapy.

Is NCT07000162 still recruiting?

NCT07000162 is currently recruiting now. Last updated 29 August 2025.

Last reviewed 2025-08-29 · How we verify

NCT07000162: LART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial

Recruiting now Phase 2 Last updated 29 August 2025

What this trial tests

Phase 2 trial testing Lattice radiation therapy in Cancer in 56 participants. Currently enrolling.

Timeline

26 May 2025

Primary endpoint
1 May 2027

1 May 2028

Quick facts

Lead sponsor	Azienda USL Reggio Emilia - IRCCS
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	26 May 2025
Primary completion	1 May 2027
Estimated completion	1 May 2028
Sites	1 location across Italy

Drugs / interventions tested

Lattice radiation therapy

Conditions studied

Cancer — all drugs for Cancer →
Palliative Radiotherapy — all drugs for Palliative Radiotherapy →

Sponsor

Azienda USL Reggio Emilia - IRCCS — full company profile →

Who can join

18 and older, any sex, with Cancer or Palliative Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the activity and toxicity of Lattice Radiation Therapy (LRT) in patients with large, unresectable non-brain neoplastic lesions requiring palliative treatment. Eligible patients will 5 fractions LRT, delivered in every other day, to 20 Gy with a simultaneous boost to a minimum median dose of 50 Gy. No concomitant antineoplastic drugs will be allowed. Patients will be followed at 14, 30, 60, and 90 days after treatment, then every 3 months up to 1 year. Tumor response will be assessed using objective response rate (ORR) per RECIST 1.1, with CT scans at 3, 6, 9, and 12 months. Secondary endpoints include local control, toxicity (CTCAE v.5.0), and patient-reported outcomes (PROMs) to assess their quality of life (EORTC QLQ-C15-PAL and PRO-CTCAE). Exploratory objectives will assess the immunomodulatory effects of LRT through immune cell characterization and quantification of immune-related circulating factors before and after treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges.
Di Franco R, Mottareale R, Pezzulla D, Mercogliano S, et al · · 2026 · PMID 42174670 · DOI 10.1186/s13014-026-02860-7
Metabolism-Guided LATTICE Radiotherapy in an Elderly Patient with Locally Advanced Head and Neck Cancer Treated with Curative Aim: A Case Report.
Iati' G, Parisi S, Ferrantelli G, Pergolizzi S. · · 2025 · PMID 41283581 · DOI 10.3390/reports8040213

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Azienda USL Reggio Emilia - IRCCS trials

Trials by the same sponsor.

NCT07373626 — Physical Activity Trends in Cancer Survivors Treated at the 'MOvement and REhabilitation' Clinic · recruiting
NCT06629896 — Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomize · NA · recruiting
NCT06749600 — Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma · recruiting
NCT06624280 — Does Orthopedic Surgery Improve Gait Efficiency in Children With Cerebral Palsy? A Retrospective Study · completed
NCT07339319 — Treatment and Outcome of Patients With Mild Head Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07000162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda USL Reggio Emilia - IRCCS
Last refreshed: 29 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07000162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing